Cogent closes upsized $172.6M public offering of common stock and pre-funded warrants

Cogent Biosciences, Inc.

Gross proceeds ~$172.6M from 17,899,698 shares at $8.25 and 3,030,302 pre-funded warrants at $8.24.
Net proceeds to fund development and commercial activities for bezuclastinib and other candidates.
Underwriters exercised in full their option to purchase 2,730,000 additional shares.
Pre-funded warrants exercisable at $0.01 per share, subject to 9.99% beneficial ownership limitation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.